IL17RB

Across TCGA pan-cancer cohorts, IL17RB mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IL17RB data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher IL17RB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IL17RB expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM and CCRCC are the cancer types where IL17RB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.722	0.413	.007	3	view →
CCRCC	DFS	Median	All	0.843	0.649	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IL17RB–GBM (DFS)

Open the GBM breakdown →